HDDO 1756
Alternative Names: HDDO-1756Latest Information Update: 28 Jul 2023
Price :
$50 *
At a glance
- Originator Hyundai Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in South Korea
- 06 Apr 2020 HDDO 1756 is available for licensing as of 06 Apr 2020. http://www.hyundaipharm.co.kr/
- 06 Apr 2020 Preclinical trials in Endocrine disorders in South Korea before April 2020 (Hyundai Pharma pipeline, April 2020)